Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9306 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 2026 Sep 8, 2025 Jan 12, 2026 In Use
J9326 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 Jan 12, 2026 In Use
C9287 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2012 Dec 31, 2012 No Longer Used
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
C9131 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jul 1, 2013 Dec 31, 2013 No Longer Used
C9146 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct 1, 2019 In Use
J9273 Tisotumab vedodin-tftv Tivdak 1mg Immunotherapy Drug Antibody Conjugate Tissue factor No 2021 Mar 25, 2022 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
J9359 Loncastuximab tesirine-lpyl Zynlonta 0.075mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Mar 25, 2022 In Use
J9053 Belantamab mafodotin-blmf Blenrep 0.1mg Immunotherapy Drug Antibody Conjugate BCMA No 2024 Jun 17, 2026 In Use
C9004 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9300 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2002 In Use
C9066 Sacituzumab govitecan-hziy Trodelvy 10mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Oct 1, 2020 Jan 1, 2021 In Use
C9174 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I No 2025 Jul 9, 2025 Sep 8, 2025 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 Jul 1, 2020 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
J9011 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 No 2025 Sep 8, 2025 In Use
J9042 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2013 In Use
J9203 Gemtuzumab ozogamicin Mylotarg 0.1 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2018 In Use
NA Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Yes 1978 In Use
S0146 Peginterferon Alfa-2b Pegintron, Sylatron 20 mcg/mL Immunotherapy Cytokine Interferon No 2001 Jul 1, 2005 Sep 30, 2010 No Longer Used
S0145 Pegintereferon Alfa-2a Pegasys 180 mcg/mL Immunotherapy Cytokine Interferon No 2002 Jul 1, 2005 In Use
J9216 Interferon Gamma-1b Actimmune 3 million units Immunotherapy Cytokine Interferon No 1999 Jan 1, 2009 In Use
J9160 Denileukin Diftitox Ontak 300 mcg Immunotherapy Cytokine Interleukin-2 No 1999 Jan 1, 2001 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.